Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review

References

• Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013;88:798–802. doi:10.1002/ajh.23467. PMID:23695956.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19:1921–6. doi:10.1093/annonc/mdn392. PMID:18573805.
   PubMed Web of Science ®Google Scholar
• Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, Hashimoto C, Takemura S, Taguchi J, Sakai R, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2010;28:27–32. PMID:19358143.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21:2069–74. doi:10.1093/annonc/mdq057. PMID:20231297.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22:1601–7. doi:10.1093/annonc/mdq627. PMID:21199885.
   PubMed Web of Science ®Google Scholar
• Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, et al. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91:395–9. doi:10.1002/ajh.24299. PMID:26800311.
   PubMed Web of Science ®Google Scholar
• Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98:415–21. doi:10.1111/ejh.12847. PMID:28039906.
   PubMed Web of Science ®Google Scholar
• Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med. 2011;208:67–80. doi:10.1084/jem.20101499. PMID:21220451.
   PubMed Web of Science ®Google Scholar
• Rosen A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Björkholm M, Jansson M, Mansouri L, et al. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology. 2012;1:18–27. doi:10.4161/onci.1.1.18400. PMID:22720208.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Oka K, Hiasa A, Yamaguchi M, Ohno T, Kita K, Shiku H. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood. 1998;91:1145–51. PMID:9454743.
   PubMed Web of Science ®Google Scholar
• Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002;100:4537–43. doi:10.1182/blood-2002-05-1525. PMID:12393419.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6:5615–33. doi:10.18632/oncotarget.3479. PMID:25760242.
   PubMedGoogle Scholar
• Miyazaki K, Yamaguchi M, Imai H, Kobayashi K, Tamaru S, Kobayashi T, Shiku H, Katayama N. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. Int J Hematol. 2015;102:188–94. doi:10.1007/s12185-015-1812-2. PMID:26009281.
   PubMed Web of Science ®Google Scholar
• Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology. 2013;2:e26494. doi:10.4161/onci.26494. PMID:24482747.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33:251–7. doi:10.1200/JCO.2014.55.5714. PMID:25135992.
   PubMed Web of Science ®Google Scholar
• Garciaz S, Coso D, Schiano de Colella JM, Bouabdallah R. Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2016;25:1103–16. doi:10.1080/13543784.2016.1208170. PMID:27414850.
   PubMed Web of Science ®Google Scholar
• Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160:487–502. doi:10.1111/bjh.12172. PMID:23252516.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650–7. doi:10.1158/1078-0432.CCR-07-4405. PMID:18628480.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2015;33:2803–11. doi:10.1200/JCO.2014.59.5363. PMID:26195701.
   PubMed Web of Science ®Google Scholar